1014 ET - The danuglipron setback has pushed Pfizer to the sidelines in the booming obesity market, but Viking Therapeutics' VK2735 could get the drugmaker back in the game, say analysts at William Blair. In a note, Andy Hsieh and Alexandra Ramsey say VK2735, in development as a pill and as an injection, could offer Pfizer a rare opportunity to reestablish not only a mere presence in obesity, but also a leading position beyond the current Novo Nordisk/Eli Lilly duopoly. With shares down significantly over the past six months, Viking sports a market cap of around $2.5 billion, but William Blair sees a fair value of $9.2 billion, or about $82 a share. Viking surges 9.7% to $24.43. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 10:14 ET (14:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。